ArticleACS omega2023
In Vivo and in Vitro Regulatory Effect of Silibinin on Some Metabolic Enzyme Activities against Cobalt Induced Toxicity in Rats: A Biochemical Approach.
Article in ACS omega, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 2 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The study aimed to examine the in vivo inhibition effect of cobalt ion and silibinin on metabolic enzymes such as glucose-6-phosphate dehydrogenase (G6PD), 6-phosphogluconate dehydrogenase (6PGD), glutathione reductase (GR), and glutathione S-transferase (GST) and their in vitro inhibition effect on 6PGD. Twenty-four Wistar Albino rats weighing approximately 250-300 g were used in the study. The rats were divided into 4 groups as group 1 (control): isotonic serum (0.5 mL i.p), group 2 (cobalt): (150 mg kg/day cobalt), group 3 (silibinin): (100 mg/kg/day silibinin), group 4 (cobalt + silibinin). As a result of the in vivo applications, a statistically significant decrease was observed in the activities of G6PD (
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.